Zhou Jiahua, Li Jiajing, Pan Qiuwei, Ayada Ibrahim
Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.
J Clin Transl Hepatol. 2024 Aug 28;12(8):750-754. doi: 10.14218/JCTH.2024.00059. Epub 2024 Jul 1.
Both alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease are leading contributors to chronic liver diseases. These conditions often coexist, exacerbating disease progression. Despite ALD being a leading cause of liver transplantation, many individuals with alcohol use disorder (AUD) do not receive treatment. In this review, we discussed the epidemiology of ALD in AUD, various treatment options for AUD, and their efficacy on liver health. Our critical analysis of current evidence underscores the need for integrated models involving multiple stakeholders to improve ALD management.
酒精性肝病(ALD)和代谢功能障碍相关脂肪性肝病都是慢性肝病的主要病因。这些情况常常并存,加剧疾病进展。尽管ALD是肝移植的主要原因之一,但许多酒精使用障碍(AUD)患者并未接受治疗。在本综述中,我们讨论了AUD中ALD的流行病学、AUD的各种治疗选择及其对肝脏健康的疗效。我们对现有证据的批判性分析强调了需要多方利益相关者参与的综合模式来改善ALD的管理。